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Abstract
Turner syndrome is a rare genetic disorder which impairs women’s growth, reproductive function, cardiovascular development and other 
functions. This syndrome has been proposed as an independent risk marker for cardiovascular disease. Despite this, life-threatening 
cardiovascular outcomes affecting young women are dismissed because of incomplete follow up. During assessment due to their smaller 
stature, it should be noted that, although the ascending aorta diameter is normal in absolute terms, after indexation for body size, patients 
with Turner syndrome may have a dilated aorta.
Based on recent guidelines and the latest studies, there is new evidence on the use of magnetic resonance imaging in diagnosing aortic 
lesions. New management possibilities of aortopathies have also been discussed. This approach should optimise medical care for women 
with Turner syndrome, but many areas of uncertainty still remain in the diagnosis and management of this syndrome, and new prospec-
tive studies are needed. (Endokrynol Pol 2015; 66 (1): 58–65)
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Streszczenie
Zespół Turnera jest rzadko spotykanym schorzeniem o podłożu genetycznym u kobiet, u których występują między innymi za-
burzenia wzrastania, płodności oraz zaburzenia w rozwoju układu sercowo-naczyniowego. Obecnie uważa się, że zespół Turnera 
jest niezależnym czynnikiem ryzyka rozwoju chorób układu sercowo-naczyniowego. Pomimo istotnego ryzyka rozwoju powikłań, 
które mogą nawet zagrażać życiu młodych pacjentek, wiele z nich odsyłanych jest do domu bez pogłębionej diagnostyki w kie-
runku zaburzeń w układzie sercowo-naczyniowym. Należy zauważyć, że chociaż wymiary aorty wstępującej są u wielu pacjentek 
obarczonych zespołem Turnera prawidłowe, to po uwzględnieniu rzeczywistych wymiarów ciała pacjentki można stwierdzić, że 
u części z nich aorta jest poszerzona.
Opublikowane ostatnio wyniki badań oraz zalecenia kliniczne wskazują na przydatność rezonansu magnetycznego (MRI, magnetic re-
sonance imaging) w diagnostyce zmian organicznych aorty. W publikacji omówiono także nowe możliwości terapeutyczne w przypadku 
występowania zmian w aorcie, co mogłoby usprawnić leczenie pacjentek z zespołem Turnera. W dziedzinie diagnostyki i leczenia tego 
zaburzenia genetycznego istnieje jednak nadal wiele nierozwiązanych zagadnień, dlatego też konieczne jest prowadzenie dalszych badań, 
także o charakterze prospektywnym. (Endokrynol Pol 2015; 66 (1): 58–65)
Słowa kluczowe: zespół Turnera; zaburzenia budowy aorty; leczenie
Epidemiology, diagnosis and genetics  
of Turner syndrome
Turner syndrome (TS) is a rare congenital disorder 
caused by sex chromosome haploinsufficiency in a 
phenotypic female, associated with characteristic clini-
cal features: short stature, primary amenorrhoea and 
cardiovascular pathology [1, 2].
The prevalence of TS is 50 per 100,000 live born 
females in Caucasian populations [2, 7]. Prenatal 
prevalence is much higher than the postnatal, be-
cause of the frequent intrauterine mortality [1, 37]. If 
TS is suspected in the intrauterine period, postnatal 
confirmation must be done [3]. Postnatal diagnosis 
requires a standard 30-cell karyotype which identi-
fies at least 10% mosaicism with 95% confidence 
[5, 6]. Specific clinical findings are also required for 
the diagnosis. Individuals with a 45,X without clinical 
features are not considered to have TS; phenotypic 
males are also excluded from the diagnosis of TS, 
regardless of the karyotype [3].
TS is related to various karyotypes [4]. A correlation be-
tween karyotype and phenotype has been reported [4, 18]. 
The most severe phenotypes are 45,X and 46,XXp [4, 37].
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genetic-based, and traumatic diseases [19, 20, 24, 27, 29]. 
Aneurysms and dissections are major diseases of the 
aorta that lead to lethal outcomes [19]. There are two 
major types of thoracic aortic aneurysms (TAA) — de-
generative/atherosclerotic and genetically triggered [22, 
24, 27]. The most dangerous thoracic aortic aneurysms 
that lead to dissection of ascending aorta are usually 
associated with genetic mutations [26, 30].
The genetic background causing the lesion of 
ascending aorta in TS remains poorly understood 
[17, 47]. Aortic root dilatation does not appear to be 
related to atherosclerosis and is more likely to be due 
to a mesenchymal defect caused by genetic disorder 
[32, 35]. The most common histological finding of the 
dilated aorta is elastic fibber fragmentation and cystic 
medial degeneration [10, 21, 30, 31, 38]. These findings 
are associated with various connective tissue diseases 
such as Marfan or Turner syndromes, etc. There has 
been some research about the influence of disruption of 
the transforming growth factor b pathway [14], which 
causes lesion of ascending aorta [23]. Further research 
into the genetic aetiology of the cardiovascular pheno-
type of TS is needed [37].
Aortopathy in Turner syndrome
Cardiovascular phenotype of TS includes generalised 
vasculopathy characterised by arterial dilation, vessel 
wall thickening, and abnormal pulse wave propagation 
[34, 37]. Aortic diameter is the principal risk stratification 
tool for aortic dissection [20, 32, 34]. 
Important findings relating to cardiovascular pathol-
ogy in TS patients have been demonstrated in a French 
Cardiovascular phenotype in Turner 
syndrome 
The most serious, life-threatening issues of X-chromo-
some haploinsufficiency are caused by lesions of the 
cardiovascular system [3, 10]. Due to a very high rate 
of spontaneous abortions (99% in 45,X karyotypes), 
congenital heart disease occurs in about 25–45% of 
live-born girls with TS versus 75% of foetuses [5, 10].
Epidemiological studies have revealed a three-fold 
higher mortality in the TS population than the general 
population, because of the cardiovascular events affecting 
young women [9, 14]. Cardiovascular findings occurring 
in TS might be congenital or acquired [18]. Congenital 
cardiovascular defects in TS are associated mainly with 
left-sided malformations (Table I). Elongated transverse 
arch of the aorta (ETA) is seen in 50% of women with TS, 
and bicuspid aortic valves (BAV) in 13–43%, versus 1–2% 
in the general population [13, 25] and coarctation of the 
aorta (CoA) in 4–18% in those with TS [7, 11, 13].
The value of the partial fusion of the aortic valve has 
been discussed recently. Traditionally, it was thought 
that this is an acquired valve problem, but a recent study 
[58] has shown equal distribution across all age groups. 
It has also been found that partial fusion of the aortic 
valve has an influence on increasing ascending aortic 
diameter in subjects with TS. 
Acquired cardiovascular problems in women with 
TS may be caused by a number of risk factors, includ-
ing central obesity, impaired glucose tolerance, insulin 
resistance, and hyperlipidaemia [8, 12, 15, 16, 18]. More 
than 30% of young girls and adolescents, as well as 50% 
of adults with TS, are mildly hypertensive on 24-hour 
ambulatory blood pressure measurements, and an ad-
ditional 50% display abnormal circadian blood pressure 
profile in the same age group [7, 11]. 
The mechanism has not been clearly identified: an 
increase in plasma rennin activity has been found in 50% 
of cases by some authors [11]. Conversely, normal rennin 
and aldosterone has been reported in another study [10]. 
Women with TS should undergo annual screening 
for cardiovascular risk factors [12].
Monitoring is based on expert consensus and 
includes clinical and laboratory evaluation, blood 
pressure measurement, echocardiography, and cardio-
vascular magnetic resonance imaging [3, 14, 27] but the 
follow-up remains quite poor.
This paper is focused on the aortic events which are 
characteristic for TS.
Thoracic aortic disease 
In general, the term ‘thoracic aortic disease’ encompass-
es a broad range of degenerative, structural, acquired, 
Table I. The prevalence of congenital cardiovascular defects 
in Turner syndrome
Tabela I. Częstość występowania wad wrodzonych układu 
sercowo-naczyniowego u pacjentek obarczonych zespołem 
Turnera
BAV (%) Coarc (%) ETA (%)
Mortensen [10] 15–30 17 50
Gotzsche [13] 14 10 NR
Sybert [13] 14 14 NR
Mazzanti [13] 12 7 NR
Volkl [13] 18 18 NR
NIH 30 12 49
Donadille [14] 21 6.9 1
Lopez [34] 26 17 NR
Mortensen [43] 27.3 13.3 47.4
Kim [45] 39.2 15.7 31.4
BAV — bicuspid aortic valve; Coarc — aortic coarctation; ETA — elongated 
transverse arch of aorta; NR — not reported; NIH — National Institutes of Health
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cohort study [14]. The whole population with TS in 
France was evaluated. This study detected a rather poor 
cardiovascular monitoring in this population. 
Cardiovascular data of 233 patients (children and 
adults) with TS was analysed, and only 38.6% of the 
cohort had undergone both echocardiography and MRI 
evaluation. BAVs were detected in 49 patients (21%) 
with a median age of detection being 20 years. Aortic 
coarctation was detected in 16 cases (6.9%). At least one 
aortic diameter exceeded 32 mm in 28 cases (12%), but 
after indexation to body size 91 (39%) patients from the 
cohort had at least one aortic diameter over 20 mm/m2. 
There is more data showing that the prevalence of as-
cending aortic dilation is about 15–30% in TS patients, 
and usually it is asymptomatic [6, 12, 33]. Despite 
a normal ascending aortic diameter in absolute terms, 
after indexation for body size, patients with Turner 
syndrome may have a dilated aorta [10, 20, 37, 39, 44]. 
Two major strategies have been proposed to circum-
vent the size problem: the first is to use body surface 
area (BSA), the second is to use ascending/descending 
aortic diameter (AD/DD) ratios [35]. Significant aortic 
dilatation is defined by a ratio > 1.5 [13]. All measure-
ments of the aorta should be done at the end of systole 
[3].
In patients with Turner syndrome, aortic dilata-
tion is present when the maximum aortic diameter 
is greater than 2.0 cm/m2, and at ≥ 2.5 cm/m2 there is 
a high risk of aortic dissection [12, 20] Paediatricians 
usually adjust aortic diameters to body surface area 
using Roman nomograms or more recent normative 
data [37]. The DuBois and DuBois formula is used 
to estimate the approximate body surface area for 
adults [14].
Statistically significant relationships between 45,X 
karyotype and BAV, as well as between 45,X and aortic 
dilatation, were confirmed in the French cohort study 
and a more frequent cardiovascular follow-up for pa-
tients with X monosomy was strongly recommended 
[14]. Mortesen et al. did not find a direct influence of 
karyotype on the diameter of aorta, but it is probably 
associated with the indirect influence via bicuspid aortic 
valve and aortic coarctation [48]. High prevalence of 
BAV and aortic coarctation in a case of missing only the 
short arm (p) of X chromosome has also been reported 
[56]. This indicates that haploinsufficiency for Xp genes 
contributes to abnormal aortic valve and aortic arch 
development in TS [56]. 
The main risk factors for increased aortic size in 
TS are: hypertension, presence of BAV, aortic coarc-
tation, and 45,X karyotype [17, 34, 37, 43, 44, 46, 48]. 
Hypertension leads to increased risk and progression 
of aortic dilation [23, 26]: the growth rate of the aorta 
is about 0.07 to 0.2 cm/y but it can be accelerated by 
hypertension [28]. Mortesen et al. found even more ag-
gressive aortic growth rates in TS, ranging from 0.20 to 
0.38 mm/year [48].
Table II. Aetiology of thoracic aortic disease [30]
Tabela II. Etiologia rozwoju zmian w odcinku piersiowym 
aorty [30]
Aetiology Details
Degenerative  
aneurysms
Atherosclerotic
Most common
Associated with hypertension, age, smoking
More commonly involves the descending aorta 
and arch
Genetically triggered aneurysm syndromes
Marfan syndrome Most common inherited connective tissue disease
Mutation in FBN-1 gene leads to decreased tensile 
strength of the aorta
Estimated that 75% of patients will have a dilated 
aortic root
Loeys-Dietz 
Syndrome
Aggressive vasculopathy linked to TGFBR1  
or 2 mutation
Early detection and intervention is important
Bicuspid aortic 
valve
> 50% have tubular/ascending aneurysm
20% sinus of Valsalva involvement
Faster rate of growth than aneurysms associated 
with a three leaflet valve
Turner syndrome 1/3 with bicuspid valve and coarctation of the 
aorta
Ascending aortic aneurysm
Familial non-
syndrome thoracic 
aortic aneurysm
syndrome
Dilated aorta
Absence of other connective tissue disease
Family history dissection/aneurysm
Aortitis
Infectious Syphilis (historical)
Salmonella
Staphylococcal species
Mycobacterium
Non infections/
inflammatory
More common:
Giant cell and Takayasu’s arteritis
Less common:
Behcet’s syndrome, Cogan’s syndrome, relapsing 
polychondritis
Rare:
Rheumatoid arthritis, spondyloarthropathies
Trauma Typical location is at the aortic isthmus
— Complications include rupture, 
pseudoaneurysm, chronic dissection with 
secondary aneurysm
formation
Chronic aortic 
dissection
— Aneurysm due to growth and pressure 
differential of false lumen
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The age-related increase in the aortic root diam-
eter is greater than that seen in normal women, and 
the optimal time for repeating aortic measurements 
is not clearly defined yet [11]. However, aortic root 
dilatation may occur in the absence of risk factors in 
approximately 5% of females with TS, indicating that 
all females with TS should be monitored for aortic root 
dilatation [32, 34, 35, 40].
Thoracic disease guidelines emphasise that all 
patients with Turner syndrome should undergo imag-
ing of the heart and aorta for evidence of pathological 
cardiovascular findings. If initial imaging is normal, 
and there are no risk factors for aortic dissection, repeat 
imaging should be performed every 5–10 years; if ab-
normalities exist, an annual follow up is necessary [27]. 
Despite these guidelines and Turner syndrome clinical 
practice guidelines that were published in 2007, clinical 
monitoring for cardiovascular lesions is insufficient, as 
shown in the French cohort study [14, 57]. This revealed 
that only 3.5% of patients with TS are being followed 
in accordance with National Institute of Health recom-
mendations [14].
Aortic dissection in Turner syndrome
According to the 2010 thoracic aortic disease recommen-
dations, TS is considered one of the high risk conditions 
that cause aortic dissection [27]. 
The only available epidemiological information on 
aortic dissections in TS comes from the Danish Registry. 
The study reported a rate of 78 cases/100,000 years of 
patient observation for TS versus 1 case/100,000 for the 
30- to 40-year-old female population in Denmark [35]. 
The risk is higher with age and during pregnancy [55].
The average age for dissection within the Danish co-
hort was 35 years, and 25% had no apparent risk factors 
for aortic dissection [35]. In contrast, the International 
Registry of Acute Aortic Dissection found that the mean 
age of dissection in non-TS women is 68 years [36, 38]. 
Risk for acute aortic dissection is increased by more 
than 100-fold in young and middle-aged women with 
TS [10, 12, 37]. Aortic dissection at a younger age is seen 
only in patients with connective tissue disorders (Table 
II) caused by genetic mutations [38].
In TS, aortic dissections predominantly include the 
ascending aorta (63%), with isolated descending aortic 
involvement occurring less frequently (37%) [10, 37].
The risk factors for dissection include: hypertension, 
karyotype 45,X, left-sided obstructive lesions including 
a bicuspid aortic valve, coarctation and dilated aortic 
root [10, 17, 38, 48]. The aortic growth rate is consid-
ered an additional risk factor for aortic dissection. The 
longest aortic follow-up study (4.8 years) in TS patients 
confirms the findings of previous studies about the 
aggressive nature of aortic disease in TS, with growth 
rates ranging from 0.20 to 0.38 mm/year [48]. 
Aortic dissection is the most serious complication 
in Turner syndrome, but it is has not been granted suf-
ficient consideration. Patients with Turner syndrome 
should be offered a protocol for clinical follow-up simi-
lar to that offered to patients with Marfan syndrome, 
and each clinic should establish a suitable programme 
for follow-up [38].
Radiological evaluation of cardiovascular 
abnormalities in Turner syndrome
Because of the potentially lethal cardiovascular abnor-
malities, complete cardiac evaluation has been recom-
mended for all patients when TS is diagnosed [3, 45]. 
Patients with TS should undergo imaging of the heart 
and aorta looking for possible changes e.g. bicuspid aor-
tic valve, coarctation or dilatation of the aorta [3, 27, 46]. 
Echocardiography has become the most common 
imaging test in the evaluation of cardiovascular dis-
ease and plays an important role in the diagnosis and 
follow-up of aortic diseases [39]. Transthoracic echo-
cardiography visualisation can be adequate in many 
cases under expert cardiologist guidance, but it is not 
the technique of choice for overall assessment of the 
aorta; magnetic resonance imaging, which allows bet-
ter visualisation of thoracic aorta, should be performed 
instead [6, 12, 39]. Recent guidelines suggest that girls 
who have only had echocardiography should undergo 
MRI when old enough to cooperate with personnel 
during the procedure and then every 5–10 years as 
adults [3]. Transoesophageal ECHO is too invasive for 
a screening examination [40], though transthoracic 
echocardiography visualisation is useful for the diag-
nosis and follow-up of some segments of the aorta [39, 
44]. The value of echocardiography as a screening tool 
in the TS population may be suboptimal secondary to 
widespread abnormal chest dimensions, rendering 
achievement of appropriate echocardiography acoustic 
windows difficult [37, 44].
Several studies in Denmark, France, the UK and 
the USA have evaluated the benefits of MRI in aortic 
dilation diagnosis [40–46, 48]. Despite recent guidelines 
for monitoring patients with thoracic aorta lesions, the 
sites of measurements of aorta are not clearly defined 
[3, 27, 57]. There are eight main positions where aorta 
measurements are taken, and they have been described 
in previously mentioned studies [43, 44, 46, 48]: sino-
tubular junction (pos 1); ascending aorta at the level 
of the right pulmonary artery (pos 2); ascending aorta 
proximal to the innominate artery (pos 3); aortic arch 
midway between the innominate and the left common 
carotid arteries (pos 4); aortic arch just proximal to the 
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left subclavian artery (pos 5); the isthmus distally to the 
left subclavian artery (pos 6); descending aorta at the 
level between the left pulmonary artery and the top of 
the left atrium (pos 7); and descending aorta at the most 
caudal border of the left atrium (pos 8). 
One of the largest studies evaluating aortic events in 
TS was performed by Mortesen et al. in 2013. This was 
a prospective, long-term (4.8 years) follow-up study. 
102 adults with TS were evaluated. MRI was used to 
identify the changes of aortic diameter. This study 
showed that CoA, BAV, age, diastolic blood pressure, 
body surface area and use of antihypertensives were 
variables that significantly influenced aortic diameter in 
at least one position. From these findings, the authors 
generated mathematical models to be used in clinical 
practice which allow prediction of aortic dimensions 
and changes in dimensions, taking into account other 
risk factors. ETA was first described in 2004 in the first 
MRI study that evaluated the anatomy of thoracic 
vessels in TS: in women with TS, the most common 
arterial finding was elongation of the transverse arch 
(ETA; 42/85, 49%), which was typically described as 
increased distance between the origins of the left com-
mon carotid and the left subclavian arteries [42]. ETA is 
a clinically silent anomaly and only detectable by MRI. 
It is seen in almost 50% of women with TS [12]. Elon-
gated transverse aortic arch and aortic coarctation were 
predominantly found in patients with 45,X compared 
to other karyotypes [43]. 
In summary, ETA is also found to be associated 
with higher systolic and diastolic blood pressures, 45,X 
karyotype, the presence of neck webbing, the presence 
of left superior vena cava, left subclavian artery dilata-
tion, bicuspid aortic valve, and aortic dilatation [12, 43, 
47]. Some data suggests that this pathological finding 
should be added to the growing list of risk factors for 
aortic dilation in Turner syndrome [43], but the real 
meaning of this pathology remains unclear. 
The advantages of MRI include the ability not only 
to identify anatomic variants of aortopathies but also to 
assess branch artery involvement, and diagnose aortic 
valve pathology, as well as left ventricular dysfunction 
without exposing the patient to either radiation or io-
dinated contrast compared to computed tomographic 
imaging [27].
A recent study has shown that anatomic assessment 
of the aortic valve using transthoracic echocardiography 
might be inadequate: the 208 participants underwent 
transthoracic echocardiography and MRI evaluation. 
The frequency of inadequate and discrepant echocar-
diography studies among the paediatric subjects was 
11% and 14% among adults [58].
Generally, MRI is more sensitive than echocardi-
ography in detecting the aortic pathology. Ostberg et 
al. reported that 16% of women with TS had dilation 
of aorta in echocardiography. When measured using 
cardiac MRI, they determined that 33% of TS women 
had significant dilation [37]. In another study [44], 
only 35% of the women with TS who were diagnosed 
with dilation at more than one position by cardiac MRI 
were identified by echocardiography. In this study, 
echocardiography was sensitive to severe aortic dila-
tation (aneurysm) but less sensitive to less progressed 
dilatation as well as to dilatation at more positions [44]. 
Dilatation of the aorta, particularly in the descending 
portion, is not well imaged by echocardiography, and 
the prevalence of those patients considered to have 
aortic dilatation is increased using MRI [47].
Monitoring should be undertaken using MRI, the 
most appropriate modality allowing complete evalua-
tion of the thoracic aorta [40]. MRI can identify aortic 
root anomalies missed on an echocardiogram [41].
However, transthoracic echocardiography seems to be 
more sensitive than MRI in detecting valvular patholo-
gies, when assessing aortic valve function [40, 43, 46, 58].
On the other hand, there may be contraindications 
to MRI use in patients with indwelling metal-containing 
devices or implants, and it may not be tolerated well 
by all TS patients due to anxiety that is common in this 
population [47]. In contrast to MRI, echocardiography 
is universally accessible, quick, cheap, safe, and never 
contraindicated [44].
Turner syndrome and pregnancy 
Spontaneous pregnancies have been reported in 2% 
to 5% in TS. Oocyte donation has made it possible for 
many women with TS to become pregnant [66]. Increas-
ing numbers of women with TS are seeking pregnancy 
with modern reproductive technologies [57]. However, 
this population with a high prevalence of cardiac mal-
formations is considered as very high-risk pregnancies 
[61–64]. The overall risk for major pregnancy complica-
tions in TS women is approximately 10% and the risk 
of maternal death is approximately 3.5% [64]. The risk 
of aortic dissection is significantly increased during 
pregnancy, particularly in the third trimester, with 
mortality from aortic dissection during pregnancy in 
excess of 100 times the general population risk [57, 
65]. The rate of aortic dissections associated with TS 
pregnancies published in case reports is 4.8% [64]. Re-
cent guidelines recommend a cardiovascular check-up 
before pregnancy [59]. Aortic diameters above 25 mm/
m2, aortic coarctation, and a history of aortic surgery are 
considered contraindications to pregnancy [59, 63, 64].
Only one embryo should be transferred in women 
with TS, to reduce the risk of morbidity and mortality 
due to twin gestations [62, 64].
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The first study to clearly show that pregnancies 
obtained by oocyte donation in TS are very high-risk 
pregnancies was performed in France. This was a mul-
ticentre retrospective study of about 20 years including 
all French centres that performed oocyte donation. 
93 pregnancies with TS were included in analysis and 
two cases of aortic dissection were reported [63]. An-
other retrospective cohort study which included 106 
women with TS who delivered after oocyte donation 
was performed in three Nordic countries (Finland, 
Denmark and Sweden) between 1992 and 2011. Poten-
tially life-threatening complications occurred in 3.3% 
of pregnancies. The main finding in this large Nordic 
collaborative study was that the pregnancies among 
women with TS carry a substantial risk, particularly for 
hypertensive disorders [60].
During pregnancy, women with TS should be 
closely followed by a multidisciplinary team of spe-
cialists in maternal-foetal medicine, cardiology, and 
endocrinology [65]. With appropriate screening and 
follow-up, the risk of cardiac complications is reduced 
during pregnancy and delivery [61].
Delayed diagnosis of Turner syndrome
Early diagnosis of TS improves outcomes of numerous 
health problems [55].
TS diagnosis can be established at birth or in early 
childhood, if lymphedema and webbed neck appears, 
but some postnatal diagnoses may be delayed for years, 
with 38% being diagnosed in adulthood [5, 7, 8]. The 
condition may be diagnosed fairly early if growth fail-
ure or delayed puberty occurs. Unfortunately a lot of 
patients are lost during the transition period [8]. 
Recent guidelines recommend that karyotype 
analysis should be performed in all girls with short 
stature, delayed puberty, webbed neck, lymphedema, 
and CoA. However, karyotype screening of all girls 
who have CoA for possible Turner syndrome has not 
been reported [55].
A study assessing the prevalence of Turner syn-
drome in girls presenting with coarctation of the 
aorta has been done. A large cohort (132 girls) has been 
evaluated. It found that 5.3% of girls presenting with 
CoA had Turner syndrome confirmed by karyotyping 
analysis [55].
Failure to diagnose TS is highly unfortunate because 
morbidity and mortality are higher than in the general 
population [2, 10]. In TS, cardiovascular morbidity and 
mortality are attributed to: congenital heart disease 
(SMR, 20.7), aortic dilation and dissection (SMR, 23.6), 
ischaemic heart disease (SMR, 2.8), and cerebrovascular 
disease (SMR, 3.9). All-cause mortality is raised in 45,X 
compared to mosaic karyotypes [10]. 
Early diagnosis of Turner syndrome would improve 
the outcomes of numerous health problems, including 
growth failure, autoimmune and inflammatory dis-
ease, possible gonadal malignancy, and psychological 
problems [55].
Treatment options for patients with TS
Basic medical treatment recommendations for patients 
with thoracic aortic disease were provided in guidelines 
issued in 2010: strict control of hypertension, optimisa-
tion of lipid profile, smoking cessation, and other ath-
erosclerosis risk-reduction. Antihypertensive therapy 
should be administered to hypertensive patients with 
thoracic aortic diseases to achieve a goal of less than 
140/90 mm Hg (patients without diabetes) or less than 
130/80 mm Hg (patients with diabetes or chronic renal 
disease) [27, 35]. 
There are no evidence-based recommendations for 
the treatment of TS patients with aortic dilatation. In the 
absence of such evidence, it may be helpful to borrow 
from the successful experience in treating patients with 
Marfan syndrome [34, 37]. Beta blockers, angiotensin 
converting enzyme inhibitors or angiotensin receptor 
blockers [35] are considered first line therapy for pa-
tients with Marfan syndrome because of the reduction 
in the rate of aortic dilatation [27, 35]. 
In a small cohort study, the use of ARB therapy in 
patients with Marfan syndrome significantly slowed 
the rate of progressive aortic-root dilation [52]. If 
strong evidence of treatment benefit for angiotensin 
receptor blockers in patients with Marfan syndrome 
can be obtained, the natural history of Marfan syn-
drome and aortic aneurysms due to another aetiology 
may change dramatically in future [53]. RAS blockers 
are promising new tools in treating other thoracic 
aortic diseases [54].
Careful handling of the obesity and metabolic disease 
that are common in TS may also improve aortic outcomes. 
Hypertension management is crucial in avoiding the pro-
gression of dilation, but drug trials are lacking in TS [48]. 
Numerous observational, retrospective and inter-
ventional studies in recent years, as well as those using 
animal models, have supported the hypothesis that sex 
hormone replacement therapy exerts important benefi-
cial effects on heart disease, diabetes and obesity in TS 
patients [18]. Oestrogen replacement therapy appears 
to reduce central arterial stiffness, improve endothelial 
function, and decrease carotid intima media thickness 
in short-term studies in TS [10].
There are concerns that recombinant human growth 
hormone (GH) treatment therapy could induce un-
favourable aortic wall changes and may increase the 
risk for aortal lesions, including aortic dissection and 
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rupture [10, 49]. Outcomes of studies to date have been 
controversial, as animal and human cell models have 
shown that GH may directly influence homeostasis 
within the media layer of the aortic wall [10], while 
reports on GH treatment in Turner syndrome show 
no effect on aortic or ventricular size when the data is 
adjusted for height or BSA [34].
One of the studies [50] compared aortic diameters in 
GH treated and untreated girls with TS. Both ascending 
and descending aortic diameters were increased in GH-
treated individuals, but multivariate analysis indicated 
that this increase was explained by an increase in height 
without evidence for any additional impact of GH 
treatment of cardiovascular system. Another study [51] 
reported that GH treatment of girls with TS increases 
stature but does not disproportionately affect cardiac 
dimensions. Adjusting for their larger body size, there 
were no significant differences in cardiac dimensions in 
the two groups. There is some data about the positive 
affect of reductase inhibitors (statins). 
They stop the progression of aortic aneurysms by 
reducing the inflammation in the arterial wall [29].
There is a lack of evidence-based guidelines on 
monitoring and interventions for dilated aorta in TS 
[48], just as there is no clear evidence that would help 
to define precise timings for medical or surgical inter-
vention in TS patients [44].
Management and follow up are areas that remain 
poorly developed in TS, and require further research 
and more careful monitoring.
Conclusion
Despite the high prevalence of cardiovascular pathol-
ogy affecting young women with TS, management 
of this disorder is still a challenge. The aetiology of 
aortic lesions remains poorly understood; the genetic 
background has been considered in recent studies, 
but evidence is inconsistent. Diagnosis of TS is quite 
often delayed and this can have serious medical 
consequences. Careful follow up using modern 
techniques such as MRI for cardiovascular screening 
is necessary, but usually this is still not considered 
in clinical practice. Pregnancy is much more com-
mon these days in women with TS. This condition 
requires extremely close monitoring, but experience 
for follow-up is insufficient. As of yet, no agreement 
on the best time for medical or surgical intervention 
in TS patients has been established.
In conclusion, there are numerous areas of un-
certainty in the management of Turner syndrome, 
and more careful monitoring for cardiovascular 
pathology in young women with Turner syndrome 
must be done. 
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